Wolfe Research initiated coverage of Ionis Pharmaceuticals with a Peer Perform rating. The company’s improved EBIT margins are crucial for success, yet Ionis Pharmaceuticals’ cash generation is unlikely to improve in the near-term, the analyst tells investors in a research note. Wolfe adds however that it sees little room for downside given the stock’s valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis Pharmaceuticals: FDA grants Fast Track designation to eplontersen
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
- Pharvaris price target raised to $13 from $11 at BofA
- Ionis Pharmaceuticals Reports Positive Phase 3 HAE Study Results
- Ionis Pharmaceuticals’ donidalorsen meets primary endpoint in Phase 3 HAE trial
